HK Stock Market Move | ANTENGENE-B (06996) surged over 6%, announcing the latest research results of the Phase I/II clinical study of ATG-022.

ANTENGENE-B(06996) rose by more than 6%. As of the time of writing, it has increased by 6.16% to HK$5.17 with a trading volume of HK$12.1859 million. In terms of news, on October 20th, Deqi Pharmaceuticals announced at the European Society for Medical Oncology (ESMO2025) annual meeting held in Berlin, Germany, that they have presented the latest research results of the phase I/II clinical study of the CLDN18.2 antibody-drug conjugate (ADC) ATG-022 in poster form. ATG-022 has shown good safety and significant anti-tumor activity in patients with different levels of CLDN18.2 expression in GC/GEJC, which will support its further clinical development in patients with different levels of CLDN18.2 expression. In addition to GC/GEJC, preliminary efficacy has also been observed in other non-gastrointestinal tumors, and related data will be presented at subsequent academic conferences. It is worth noting that the safety data of the 2.4mg/kg dose group is good, and the 1.8mg/kg dose group shows even better performance in terms of safety and tolerability. The company stated that this will provide strong evidence for the combination of ATG-022 with immune checkpoint inhibitors and chemotherapy in frontline treatment, potentially significantly expanding its clinical applicability and commercial potential. Currently, the phase I dose expansion study of ATG-022 in mainland China and Australia is progressing smoothly. Meanwhile, the company is actively preparing for the clinical study of the combination therapy of ATG-022 to further advance its clinical development process.